Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
McCreadie, Robin G.
Main, Christopher J.
and
Dunlop, Rosalyn A.
1978.
Token Economy, Pimozide and Chronic Schizophrenia.
British Journal of Psychiatry,
Vol. 133,
Issue. 2,
p.
179.
McCreadie, R. G.
Flanagan, W. L.
McKnight, J.
and
Jorgensen, A.
1979.
High Dose Flupenthixol Decanoate in Chronic Schizophrenia.
British Journal of Psychiatry,
Vol. 135,
Issue. 2,
p.
175.
McCreadie, RG
Heykants, JJ
Chalmers, A
and
Anderson, AM
1979.
Plasma pimozide profiles in chronic schizophrenics..
British Journal of Clinical Pharmacology,
Vol. 7,
Issue. 5,
p.
533.
Rao, V. A. Rama
Bishop, Margaret
and
Coppen, Alec
1980.
Clinical State, Plasma Levels of Haloperidol and Prolactin: A Correlation Study in Chronic Schizophrenia.
British Journal of Psychiatry,
Vol. 137,
Issue. 6,
p.
518.
Bj�rndal, N.
Bjerre, M.
Gerlach, J.
Kristjansen, P.
Magelund, G.
Oestrich, I. H.
and
W�hrens, J.
1980.
High dosage haloperidol therapy in chronic schizophrenic patients: A double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin.
Psychopharmacology,
Vol. 67,
Issue. 1,
p.
17.
Niemegeers, C. J. E.
and
Leysen, J. E.
1982.
The pharmacological and biochemical basis of neuroleptic treatment in schizophrenia.
Pharmaceutisch Weekblad Scientific Edition,
Vol. 4,
Issue. 3,
p.
71.
Linden, Robert
Davis, John M
and
Rubinstein, Joan
1982.
High vs. Low Dose Treatment with Antipsychotic Agents.
Psychiatric Annals,
Vol. 12,
Issue. 8,
p.
769.
1982.
Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
American Journal of Psychiatry,
Vol. 139,
Issue. 11,
p.
1466.
Mackay, A.V.P.
1982.
Drugs in Psychiatric Practice.
p.
42.
Johnstone, Eve C.
Crow, Timothy J.
Ferrier, I. Nicol
Frith, Christopher D.
Owens, David G. C.
Bourne, Rachel C.
and
Gamble, Stephen J.
1983.
Adverse effects of anticholinergic medication on positive schizophrenic symptoms.
Psychological Medicine,
Vol. 13,
Issue. 3,
p.
513.
Linden, Robert
Davis, John M.
and
Rubinstein, Joan
1984.
Guidelines for the Use of Psychotropic Drugs.
p.
151.
Herrera, John M.
Sramek, John J.
and
Costa, Jerome F.
1987.
Efficacy of Adjunctive Carbamazepine in the Treatment of Chronic Schizophrenia.
Drug Intelligence & Clinical Pharmacy,
Vol. 21,
Issue. 4,
p.
355.
Sramek, John J.
Potkin, Steven G.
and
Hahn, Rhoda
1988.
Neuroleptic Plasma Concentrations and Clinical Response: In Search of a Therapeutic Window.
Drug Intelligence & Clinical Pharmacy,
Vol. 22,
Issue. 5,
p.
373.
Browne, F.W.A.
Cooper, S.J.
Wilson, R.
and
King, D.J.
1988.
Serum haloperidol levels and clinical response in chronic, treatment-resistant schizophrenic patients.
Journal of Psychopharmacology,
Vol. 2,
Issue. 2,
p.
94.
Vieweg, W. Victor R.
Godleski, Linda S.
Hundley, Paul L.
and
Yan, Glenn R.
1989.
Failure of antipsychotic drug dose to explain abnormal diurnal weight gain among 129 chronically psychotic inpatients.
Progress in Neuro-Psychopharmacology and Biological Psychiatry,
Vol. 13,
Issue. 5,
p.
709.
Kane, John M.
1989.
A Clinical Guide for the Treatment of Schizophrenia.
p.
43.
Seyffart, Günter
1991.
Drug Dosage in Renal Insufficiency.
p.
279.
Abed, Riadh T
and
Bhalla, D
1991.
Persistent neuroleptic – related hypersonmia: two case reports.
Irish Journal of Psychological Medicine,
Vol. 8,
Issue. 2,
p.
130.
Shivakumar, Bangalore R.
and
Ravindranath, Vijayalakshmi
1992.
Oxidative stress induced by administration of the neuroleptic drug haloperidol is attenuated by higher doses of haloperidol.
Brain Research,
Vol. 595,
Issue. 2,
p.
256.
Collins, Evan J.
Hogan, Thomas P.
and
Awad, A.G.
1992.
The Pharmacoepidemiology of Treatment-Refractory Schizophrenia*.
The Canadian Journal of Psychiatry,
Vol. 37,
Issue. 3,
p.
192.
eLetters
No eLetters have been published for this article.